Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
105 studies found for:    GBA
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Condition: Gaucher Disease, Type 1
Interventions: Biological: velaglucerase alfa;   Biological: imiglucerase
2 Completed Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
Condition: Gaucher Disease
Intervention: Drug: Imiglucerase
3 Unknown  Intra-monocyte Imiglucerase Kinetics in Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Imiglucérase (drug) pharmacokinetics
4 Completed
Has Results
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
Conditions: Gaucher Disease, Type 1;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease;   Gaucher Disease, Non-Neuronopathic Form
Intervention: Drug: Cerezyme
5 Completed
Has Results
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Condition: Gaucher Disease, Type 1
Interventions: Drug: Eliglustat tartrate;   Drug: Imiglucerase
6 Completed
Has Results
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Biological: VPRIV®
7 Completed
Has Results
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Biological: VPRIV ®,
8 Completed A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.
Conditions: Gaucher Disease Type I;   Cerebroside Lipidosis Syndrome;   Clucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease;   Gaucher Disease, Non-Neuronopathic Form
Intervention: Drug: Cerezyme (imiglucerase for injection)
9 Not yet recruiting GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3
Condition: Gaucher Disease
Interventions: Drug: GZ/SAR402671;   Drug: Imiglucerase
10 Withdrawn Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: Adjuvant without active component
11 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
12 Recruiting Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
Condition: Gaucher Disease Type 1
Intervention: Drug: N-acetylcysteine
13 Approved for marketing Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
14 Completed
Has Results
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
Condition: Gaucher Disease, Type 1
Intervention: Biological: GA-GCB (velaglucerase alfa)
15 Completed Bone Response to Enzyme Replacement in Gaucher's Disease
Condition: Gaucher's Disease
Intervention: Drug: CEREDASE™
16 Recruiting LYSO-PROVE - Determine the Prognostic Value of Lyso-Gb1 for Monitoring the Progress of Gaucher Disease
Conditions: Lysosomal Storage Diseases;   Gaucher Disease;   Sphingolipidoses
Intervention:
17 Recruiting The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
Conditions: Gaucher Disease Type 1;   Gaucher Disease Type 3
Intervention: Drug: Velaglucerase alfa
18 Completed
Has Results
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa
19 Completed Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients
Condition: Gaucher Disease
Intervention: Drug: PRX-112
20 Completed
Has Results
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
Condition: Gaucher Disease
Intervention: Drug: GA-GCB

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years